5d 1m 3m 1y 5y 10y
There are no Transcripts on GNMSF.
There are no News articles on GNMSF.
GNMSF vs. ETF Alternatives
Thursday, Aug 302012, 8:16 AMJ&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR) |Thursday, Aug 302012, 8:16 AM| Comment!